Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million [Yahoo! Finance]
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Zevra Therapeutics Files Preliminary Proxy
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) was given a new $18.00 price target on by analysts at JMP Securities.
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $23.00 to $25.00. They now have a "buy" rating on the stock.